Study guide
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing
Philippine Medical Technologists Licensure Examination MTLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety
1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards
2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function
2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice
3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology
3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology
4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety
4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria
5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology
6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology
6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods
7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control
8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders
8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry
9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders
9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests
10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing
10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures
11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
12 Chapter 12: Clinical Serology and Immunology
12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)
13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology
13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control
14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens
14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens
15 Chapter 15: Histopathologic Techniques and Cytotechnology
15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records
16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics
16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing
Key Takeaways Explain This Topic AI
Allogeneic blood donor physical criteria require systolic blood pressure 90–180 mm Hg, diastolic 50–100 mm Hg, pulse 50–100 bpm, oral temperature ≤ 37.5 ∘ C \le 37.5^\circ\text{C} ≤ 37. 5 ∘ C ( 99.5 ∘ F 99.5^\circ\text{F} 99. 5 ∘ F ), and a minimum body weight of 110 lbs (50 kg) for a standard 450–500 mL collection.
Donors weighing under 110 lbs require proportional whole blood collection reduction: Volume to collect (mL) = [ Weight in lbs / 110 ] × 450 \text{Volume to collect (mL)} = [\text{Weight in lbs} / 110] \times 450 Volume to collect (mL) = [ Weight in lbs /110 ] × 450 , and anticoagulant removal: Anticoagulant to remove (mL) = 63 − [ ( Volume to collect / 450 ) × 63 ] \text{Anticoagulant to remove (mL)} = 63 - [(\text{Volume to collect} / 450) \times 63] Anticoagulant to remove (mL) = 63 − [( Volume to collect /450 ) × 63 ] to prevent anticoagulant excess and citrate toxicity in recipients.
Hemoglobin and hematocrit thresholds for allogeneic donation are ≥ 12.5 g/dL \ge 12.5\text{ g/dL} ≥ 12.5 g/dL (hematocrit ≥ 38 % \ge 38\% ≥ 38% ) for females and ≥ 13.0 g/dL \ge 13.0\text{ g/dL} ≥ 13.0 g/dL (hematocrit ≥ 39 % \ge 39\% ≥ 39% ) for males, whereas autologous donors require a lower threshold of ≥ 11.0 g/dL \ge 11.0\text{ g/dL} ≥ 11.0 g/dL (hematocrit ≥ 33 % \ge 33\% ≥ 33% ).
Republic Act No. 7719 (National Blood Services Act of 1994) mandates testing of all donated blood units in the Philippines for the five core transfusion-transmissible infections (TTIs): HIV-1/2, HBV, HCV, Syphilis, and Malaria.
CPDA-1 preserves red blood cells for 35 days at 1–6°C via adenine-supported ATP synthesis, whereas additive solutions (AS-1, AS-3, AS-5) extend red cell shelf life to 42 days.
Last updated: October 2026
Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing
Blood donor qualification serves as the first and most critical defense against transfusion-transmitted morbidity. In immunohematology, the donor qualification pathway integrates two equally vital mandates: protecting donor health from the physiological stresses of phlebotomy and safeguarding the recipient from infectious, immunological, or toxic complications. For medical technologists preparing for the Philippine Medical Technologists Licensure Examination (MTLE) and international certifications (such as ASCPi), mastery of regulatory donor standards, mathematical collection formulas, deferral classifications, infectious screening mandates under Republic Act No. 7719 , and anticoagulant-preservative biochemistry is essential.
1. Allogeneic Blood Donor Qualification and Physical Examination
All prospective blood donors must undergo a structured two-part assessment consisting of a confidential donor health history interview (using standardized donor history questionnaires) and a focused physical examination performed on the day of donation prior to phlebotomy. ┌──────────────────────────────────────────────┐
- │ Prospective Blood Donor Arrives │
- └──────────────────────┬───────────────────────┘
- │
- ▼
- ┌──────────────────────────────────────────────┐
- │ Confidential Health History Questionnaire │
- │ • High-risk behaviors, travel, meds │
- │ • Prior illnesses, surgeries, vaccines │
- └──────────────────────┬───────────────────────┘
- │ Passed
- ▼
- ┌──────────────────────────────────────────────┐
- │ Focused Physical Examination │
- │ • Age: ≥18 (16-17 with written consent) │
- │ • Weight: ≥110 lbs (50 kg) │
- │ • Hgb: ♀ ≥12.5 g/dL; ♂ ≥13.0 g/dL │
- │ • BP: 90-180 / 50-100 mm Hg │
- │ • Pulse: 50-100 bpm; Temp: ≤37.5°C │
- │ • Bilateral antecubital inspection │
- └──────────────────────┬───────────────────────┘
- │ Qualified
- ▼
- ┌──────────────────────────────────────────────┐
- │ Phlebotomy & Testing │
- │ • Standard 450-500 mL collection ± 10% │
- │ • Mandatory RA 7719 5 Core TTI Testing │
- └──────────────────────────────────────────────┘
- Physical Examination Criteria and Standards
Important
Philippine practice versus AABB values. Philippine blood services under the DOH National Voluntary Blood Services Program (as published by hospital blood banks and the Philippine Red Cross) accept donors aged 16 to 65 (parental consent below 18), weighing at least 50 kg (110 lb) for a 450 mL unit, with a regular pulse of 60 to 100/min , blood pressure of 90 to 160 mm Hg systolic and 60 to 100 mm Hg diastolic , and hemoglobin of at least 125 g/L (hematocrit 0.37). The AABB values used in US-based textbooks (below) differ slightly; answer local-practice questions with the Philippine criteria.
Age Requirements :
Minimum Age : ≥ 18 years \ge 18\text{ years} ≥ 18 years for autonomous legal consent. Donors aged 16 to 17 years may donate provided they present written, documented parental or legal guardian consent and satisfy all physical examination metrics.
Upper Age Limit : There is no arbitrary upper age limit according to modern AABB and Philippine Department of Health (DOH) standards, provided the donor meets all medical history and vital sign requirements and has no clinical contraindications upon evaluation by the blood service physician.
Body Weight and Blood Volume Limitations :
Minimum Weight : 110 lbs 110\text{ lbs} 110 lbs ( 50 kg 50\text{ kg} 50 kg ) for a standard whole blood collection of 450 mL ± 10 % 450\text{ mL} \pm 10\% 450 mL ± 10% (or 500 mL ± 10 % 500\text{ mL} \pm 10\% 500 mL ± 10% in designated collection systems).
Physiological Basis : Total blood collection must not exceed 10.5 mL per kilogram 10.5\text{ mL per kilogram} 10.5 mL per kilogram of donor body weight (including sample tubes), which corresponds to approximately 13 % 13\% 13% of total circulating blood volume. Drawing excessive volume relative to body mass precipitates acute hypovolemia, vasovagal syncope, and orthostatic hypotension.
Low-Weight Volume Reduction Calculation :
Donors weighing less than 110 lbs 110\text{ lbs} 110 lbs ( 50 kg 50\text{ kg} 50 kg ) who are eligible for specialized directed or autologous collections—or restricted allogeneic protocols—require proportional downward adjustments in both the volume of blood collected and the volume of anticoagulant-preservative in the collection bag. A standard primary collection pack contains 63 mL 63\text{ mL} 63 mL of anticoagulant-preservative (such as CPD or CPDA-1) designed for 450 mL 450\text{ mL} 450 mL of blood. If an under-volume unit ( < 405 mL <405\text{ mL} < 405 mL ) is collected into an unmodified 63 mL 63\text{ mL} 63 mL anticoagulant pack, the resulting excessive citrate-to-plasma ratio causes severe citrate toxicity (hypocalcemia, tetany, cardiac arrhythmias) in the recipient and distorts red cell morphology during storage.
Volume of Blood to Collect (mL) = ( Donor Weight in lbs 110 ) × 450 mL or ( Donor Weight in kg 50 ) × 450 mL \text{Volume of Blood to Collect (mL)} = \left( \frac{\text{Donor Weight in lbs}}{110} \right) \times 450\text{ mL} \quad \text{or} \quad \left( \frac{\text{Donor Weight in kg}}{50} \right) \times 450\text{ mL} Volume of Blood to Collect (mL) = ( 110 Donor Weight in lbs ) × 450 mL or ( 50 Donor Weight in kg ) × 450 mL
Anticoagulant Volume Needed (mL) = ( Volume of Blood to Collect (mL) 450 ) × 63 mL \text{Anticoagulant Volume Needed (mL)} = \left( \frac{\text{Volume of Blood to Collect (mL)}}{450} \right) \times 63\text{ mL} Anticoagulant Volume Needed (mL) = ( 450 Volume of Blood to Collect (mL) ) × 63 mL
Anticoagulant to Expel/Remove (mL) = 63 mL − Anticoagulant Volume Needed (mL) \text{Anticoagulant to Expel/Remove (mL)} = 63\text{ mL} - \text{Anticoagulant Volume Needed (mL)} Anticoagulant to Expel/Remove (mL) = 63 mL − Anticoagulant Volume Needed (mL)
Worked Clinical Calculation Example :
A directed donor weighs 90 lbs 90\text{ lbs} 90 lbs ( 40.9 kg 40.9\text{ kg} 40.9 kg ):
Blood to collect = ( 90 110 ) × 450 mL = 368.2 mL ≈ 368 mL \text{Blood to collect} = \left(\frac{90}{110}\right) \times 450\text{ mL} = 368.2\text{ mL} \approx 368\text{ mL} Blood to collect = ( 110 90 ) × 450 mL = 368.2 mL ≈ 368 mL .
Anticoagulant needed = ( 368.2 450 ) × 63 mL = 51.5 mL \text{Anticoagulant needed} = \left(\frac{368.2}{450}\right) \times 63\text{ mL} = 51.5\text{ mL} Anticoagulant needed = ( 450 368.2 ) × 63 mL = 51.5 mL .
Anticoagulant to remove = 63 mL − 51.5 mL = 11.5 mL \text{Anticoagulant to remove} = 63\text{ mL} - 51.5\text{ mL} = 11.5\text{ mL} Anticoagulant to remove = 63 mL − 51.5 mL = 11.5 mL .
The phlebotomist must aseptically express and discard 11.5 mL 11.5\text{ mL} 11.5 mL of anticoagulant from the primary bag before initiating collection.
Hemoglobin and Hematocrit Thresholds :
Allogeneic Female Donors : Hemoglobin ≥ 12.5 g/dL \ge 12.5\text{ g/dL} ≥ 12.5 g/dL ( 125 g/L 125\text{ g/L} 125 g/L ) or Hematocrit ≥ 38 % \ge 38\% ≥ 38% .
Allogeneic Male Donors : Hemoglobin ≥ 13.0 g/dL \ge 13.0\text{ g/dL} ≥ 13.0 g/dL ( 130 g/L 130\text{ g/L} 130 g/L ) or Hematocrit ≥ 39 % \ge 39\% ≥ 39% (reflecting higher baseline male reference intervals and preventing latent donor iron depletion).
Autologous Donors : Hemoglobin ≥ 11.0 g/dL \ge 11.0\text{ g/dL} ≥ 11.0 g/dL ( 110 g/L 110\text{ g/L} 110 g/L ) or Hematocrit ≥ 33 % \ge 33\% ≥ 33% .
Screening Methodologies : Quantitative automated point-of-care spectrophotometry (e.g., HemoCue) or capillary copper sulfate ( CuSO 4 \text{CuSO}_4 CuSO 4 ) specific gravity flotation. For a hemoglobin threshold of 12.5 g/dL 12.5\text{ g/dL} 12.5 g/dL , the copper sulfate solution has a specific gravity of 1.053 1.053 1.053 ; for 13.0 g/dL 13.0\text{ g/dL} 13.0 g/dL , the specific gravity is 1.055 1.055 1.055 . A drop of capillary blood that sinks within 15 seconds 15\text{ seconds} 15 seconds indicates acceptable density.
Vital Signs Tolerances :
Blood Pressure : Systolic pressure must be between 90 and 180 mm Hg 90\text{ and }180\text{ mm Hg} 90 and 180 mm Hg ; diastolic pressure must be between 50 and 100 mm Hg 50\text{ and }100\text{ mm Hg} 50 and 100 mm Hg . Moderate readings outside these boundaries require deferral until normalized or medical director authorization.
Pulse : 50 to 100 beats per minute (bpm) 50\text{ to }100\text{ beats per minute (bpm)} 50 to 100 beats per minute (bpm) , regular. Highly trained conditioning athletes exhibiting physiological resting bradycardia ( < 50 bpm <50\text{ bpm} < 50 bpm ) are acceptable provided the rhythm is regular and clinical evaluation reveals no cardiopulmonary distress.
Body Temperature : Oral temperature must not exceed 37.5 ∘ C 37.5^\circ\text{C} 37. 5 ∘ C ( 99.5 ∘ F 99.5^\circ\text{F} 99. 5 ∘ F ) . Elevations indicate active pyrexia or subclinical infection.
Skin Inspection : Bilateral antecubital fossae must be rigorously examined. Venipuncture sites must be free from localized dermatological lesions, boils, psoriasis plaques, rashes, and crucially, needle tracks or sclerotic skin punctures indicative of illicit intravenous drug abuse.
2. Donor Deferral Classifications and Regulatory Intervals
Donor deferrals are categorized according to their epidemiological duration into permanent (or indefinite) and temporary deferrals:
Permanent and Indefinite Deferrals
Individuals deferred permanently or indefinitely are excluded from allogeneic blood donation for life to prevent the transmission of incurable, fatal, or non-clearing blood-borne pathogens:
Viral Hepatitis : History of viral hepatitis, confirmed jaundice of viral etiology, or suspected hepatic infection at or after age 11 (infections occurring prior to age 11 are presumed to be benign, self-limiting Hepatitis A Virus infections and do not trigger permanent deferral).
Confirmatory Positive Serology or Molecular Testing :
Repeatedly reactive confirmed testing for Hepatitis B Surface Antigen (HBsAg) or persistent anti-HBc positivity.
Repeatedly reactive confirmed antibodies to Hepatitis C Virus (anti-HCV) or HCV RNA.
Confirmed evidence of infection with Human Immunodeficiency Virus (HIV-1/2) (anti-HIV, p24 antigen, or HIV-1 RNA).
Confirmed antibodies to Human T-Cell Lymphotropic Virus (anti-HTLV-I/II) .
Parasitic Infections with Lifelong Parasitemia :
Confirmed infection with Chagas disease ( Trypanosoma cruzi ).
Confirmed history of Babesiosis ( Babesia microti or Babesia divergens ).
Prion Disease Transmission Risk (Transmissible Spongiform Encephalopathies) :
Diagnosis of Creutzfeldt-Jakob Disease (CJD) or variant CJD (vCJD), or having a first-degree biological relative with familial CJD.
Recipients of cadaveric human pituitary-derived growth hormone (hGH) .
Recipients of cadaveric human dura mater grafts .
Cumulative geographic residence in the United Kingdom or Europe during peak bovine spongiform encephalopathy (BSE) outbreak years (subject to regional regulatory threshold updates).
High-Risk Behavioral Histories :
Any history of non-prescription intravenous (parenteral) drug abuse.
History of commercial sex work (exchanging sex for money or drugs).
Temporary Deferrals
Temporary deferrals suspend donor eligibility for a discrete interval until the infectious window period, medication clearance, or physiological recovery phase has elapsed:
Clinical Condition / Exposure Required Deferral Interval Pathophysiological Rationale
Pregnancy 6 weeks postpartum Allows replenishment of maternal iron stores and hemodynamic stabilization.
Live Attenuated Vaccines : Measles (rubeola), Mumps, Yellow Fever, Oral Polio, Typhoid (oral) 2 weeks Prevents transient subclinical vaccine viremia from transferring live viral particles to immunocompromised recipients.
Live Attenuated Vaccines : Rubella (including combined MMR), Varicella-Zoster 4 weeks Longer replication cycle and neurotropic/teratogenic potential of attenuated strains.
Blood Transfusion or Organ Transplant 3 months under current AABB standards (formerly 12 months); apply the interval in the blood service's current DOH-approved donor criteria Clears serological window periods for transfusion-transmissible pathogens.
Tattoo, Body Piercing, Accidental Needlestick 3 months under current AABB standards (formerly 12 months); many services still defer 12 months Covers window period for parenteral HBV, HCV, and HIV transmission.
Malaria Travel (endemic travel) 1 year from departure date Ensures absence of clinical malaria attacks following short-term travel.
Malaria Infection or Endemic Residence 3 years after treatment/becoming asymptomatic, or 3 years after moving from endemic area Clears latent intrahepatic dormant parasites ( Plasmodium vivax/ovale hypnozoites).
Aspirin / Platelet Inhibitor Ingestion 48 hours (for platelet donation only) Irreversible acetylation of cyclooxygenase-1 (COX-1) halts thromboxane A 2 A_2 A 2 synthesis; whole blood donation for red cells remains acceptable.
3. Republic Act No. 7719 and Mandatory Infectious Disease Testing in the Philippines
In the Philippines, blood banking operations, voluntary donor recruitment, and hemovigilance are legally anchored by Republic Act No. 7719 , known as the National Blood Services Act of 1994 . RA 7719 phased out commercial blood banks, promoting exclusively voluntary, non-remunerated blood donation to guarantee a safe, accessible, and adequate national blood supply administered under the National Voluntary Blood Services Program (NVBSP) of the Department of Health (DOH).
The Five Core Transfusion-Transmissible Infections (TTIs)
Under RA 7719 and Administrative Orders issued by the Philippine DOH, every single unit of blood collected must be tested and confirmed non-reactive for the Five Core TTIs before release for clinical issue. No blood unit may bypass this testing:
Human Immunodeficiency Virus Types 1 and 2 (HIV-1/2) :
Primary Serological Assays : 4th-generation Chemiluminescent Immunoassays (CLIA) or Enzyme Immunoassays (EIA) detecting both anti-HIV-1/2 antibodies and HIV-1 p24 antigen .
Significance : p24 antigen detection narrows the infectious seroconversion window from ≈ 22 days \approx 22\text{ days} ≈ 22 days down to approximately 12 to 16 days 12\text{ to }16\text{ days} 12 to 16 days post-exposure.
Hepatitis B Virus (HBV) :
Primary Serological Assays : Hepatitis B Surface Antigen (HBsAg) is the mandated Philippine screening marker; some blood services and most US blood centers add total antibodies to Hepatitis B core antigen (anti-HBc total) .
Significance : Testing for anti-HBc captures "occult HBV infection"—cases where circulating HBsAg has cleared below analytical detection limits or is sequestered in immune complexes during the core window phase, yet infectious viral particles persist.
Hepatitis C Virus (HCV) :
Primary Serological Assays : 3rd-generation CLIA/EIA detecting antibodies to HCV (anti-HCV) directed against core, NS3, NS4, and NS5 viral proteins.
Syphilis ( Treponema pallidum ) :
Testing Algorithm : Non-treponemal screening assays ( Rapid Plasma Reagin [RPR] or Venereal Disease Research Laboratory [VDRL] ) detecting anti-cardiolipin antibodies, accompanied or confirmed by specific treponemal assays ( Treponema pallidum Hemagglutination Assay [TPHA] , TP-PA , or recombinant treponemal EIA).
Biological Note : Treponema pallidum is a fragile spirochete that cannot survive refrigeration at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C for greater than 72 hours 72\text{ hours} 72 hours ( 3 days 3\text{ days} 3 days ). However, syphilis testing remains a mandatory surrogate marker for high-risk sexual behavior and protects recipients of room-temperature stored components (e.g., platelet concentrates).
Malaria ( Plasmodium species) :
Testing Modality : High-quality peripheral blood smear examination (thick and thin Giemsa/Wright-stained films) or approved Malaria Rapid Diagnostic Tests (RDTs) detecting Plasmodium lactate dehydrogenase (pLDH) or histidine-rich protein II (HRP-2).
Epidemiological Context : Given endemic foci across various provinces in the Philippines (e.g., Palawan, parts of Mindanao), universal screening for malaria parasites is an indispensable component of national transfusion safety.
Nucleic Acid Testing (NAT) and Window Periods
Some Philippine blood services (for example, Philippine Red Cross centers) and most high-income blood systems add Nucleic Acid Amplification Testing (NAT) (multiplex real-time transcription-mediated amplification [TMA] or PCR) for HIV-1 RNA, HCV RNA, and HBV DNA. NAT directly amplifies viral genomic material, closing the residual pre-seroconversion diagnostic window period to unprecedented safety margins:
HIV-1 Window : Reduced from roughly 16 to 18 days 16\text{ to }18\text{ days} 16 to 18 days (4th-gen serology) to about 5 to 9 days 5\text{ to }9\text{ days} 5 to 9 days with NAT (individual-donation NAT at the short end, minipool NAT at the long end).
HCV Window : Reduced from 60 days 60\text{ days} 60 days (serology) to 3 to 5 days 3\text{ to }5\text{ days} 3 to 5 days with NAT.
HBV Window : Reduced from 35 days 35\text{ days} 35 days (HBsAg) to 15 to 20 days 15\text{ to }20\text{ days} 15 to 20 days with NAT.
4. Anticoagulant-Preservative Formulations and Additive Solutions
When whole blood is collected, red cells must be preserved in specialized biochemical solutions that prevent clotting, provide glycolytic energy, buffer metabolic acid, and sustain erythrocyte membrane integrity. ┌────────────────────────────────────────────────────────┐
- │ Anticoagulant-Preservative Reagents │
- └───────────────────────────┬────────────────────────────┘
- │
- ┌──────────────────────────────────┴──────────────────────────────────┐
- ▼ ▼
- ┌───────────────────────┐ ┌───────────────────────┐
- │ Primary Anticoagulants│ │ Additive Solutions │
- │ (In Collection Bag) │ │ (Added to PRBCs) │
- └──────────┬────────────┘ └───────────┬───────────┘
- │ │
- ACD-A (21 days) • AS-1 (Adsol) - 42 days
- CPD (21 days) • AS-3 (Nutricel)- 42 days
- CP2D (21 days) • AS-5 (Optisol) - 42 days
- CPDA-1 (35 days) Mechanism:
- Mechanism of Adenine: • Saline, Dextrose, Adenine
- ATP salvage synthesis • Mannitol (AS-1, 5) stabilizes
- maintains membrane pump membrane, stops lysis
- Primary Anticoagulant-Preservative Solutions (Storage at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C )
Acid-Citrate-Dextrose (ACD-A) : 21-day shelf life . Formulated with trisodium citrate (chelates calcium to block coagulation), citric acid (maintains acidic pH), and dextrose (serves as substrate for anaerobic glycolysis).
Citrate-Phosphate-Dextrose (CPD) : 21-day shelf life . Incorporates sodium phosphate, which buffers pH to ≈ 7.2 \approx 7.2 ≈ 7.2 during early storage, preserving higher levels of 2,3-diphosphoglycerate (2,3-DPG) compared to ACD.
Citrate-Phosphate-Double Dextrose (CP2D) : 21-day shelf life . Contains 100% additional dextrose relative to CPD, fueling extended red cell glycolysis.
Citrate-Phosphate-Dextrose-Adenine (CPDA-1) : 35-day shelf life . Formulated with 0.275 mg/mL 0.275\text{ mg/mL} 0.275 mg/mL adenine alongside citrate, phosphate, and dextrose.
Biochemical Role of Adenine : Adenine serves as an essential purine substrate for the red cell salvage pathway. Erythrocytes synthesize adenosine triphosphate (ATP) from adenine, keeping intracellular ATP levels high. Elevated ATP maintains the N a + / K + Na^+/K^+ N a + / K + -ATPase pump, preserves erythrocyte membrane deformability, and suppresses membrane phospholipid loss, extending shelf life from 21 to 35 days .
Additive Solutions (AS-1, AS-3, AS-5)
Additive solutions are sterile nutrient media stored in a satellite pack ( 100 to 110 mL 100\text{ to }110\text{ mL} 100 to 110 mL ) and introduced to packed red blood cells within 72 hours of collection after plasma has been expressed. Additive solutions extend red blood cell shelf life to 42 days at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C :
AS-1 (Adsol) : Formulated with sodium chloride, dextrose, adenine, and mannitol (mannitol acts as an osmotic diuretic and membrane stabilizer that protects against erythrocyte lysis).
AS-3 (Nutricel) : Formulated with sodium chloride, dextrose, adenine, citrate, and phosphate (no mannitol; preferable for neonatal exchange transfusions to prevent osmotic diuresis).
AS-5 (Optisol) : Formulated with sodium chloride, dextrose, adenine, and mannitol.
Regulatory Standard : Units preserved with additive solutions maintain a hematocrit of 55 % to 65 % 55\%\text{ to }65\% 55% to 65% , providing superior flow rates during rapid infusion compared to CPDA-1 units ( H c t ≤ 80 % Hct \le 80\% Hc t ≤ 80% ).
The Erythrocyte Storage Lesion
During hypothermic liquid storage at 1 to 6 ∘ C 1\text{ to }6^\circ\text{C} 1 to 6 ∘ C , red blood cells undergo progressive, reversible and irreversible biochemical, structural, and physiological deteriorations known collectively as the storage lesion :
Biochemical Parameter Direction of Change Pathophysiological Consequence
Intracellular ATP Decreases ( ↓ \downarrow ↓ ) Impairs active transport pumps, causing loss of biconcave disk shape and formation of rigid echinocytes and spherocytes.
Intracellular 2,3-DPG Decreases ( ↓ \downarrow ↓ ) Drastically shifts the oxygen-hemoglobin dissociation curve to the LEFT (increased O 2 O_2 O 2 affinity, reduced oxygen delivery to hypoxic tissues). Reversible within 12–24 hours post-transfusion.
Extracellular Potassium ( K + K^+ K + ) Increases ( ↑ \uparrow ↑ ) Cold temperature slows the active N a + / K + Na^+/K^+ N a + / K + -ATPase pump while passive leakage continues, driving potassium into plasma ( > 30 to 50 mmol/L >30\text{ to }50\text{ mmol/L} > 30 to 50 mmol/L by day 35). High risk for neonates and massive transfusion.
Intracellular Sodium ( N a + Na^+ N a + ) Increases ( ↑ \uparrow ↑ ) Intracellular sodium accumulates as pump fails, contributing to cell swelling.
Plasma pH Decreases ( ↓ \downarrow ↓ ) Anaerobic glycolysis yields lactic acid; blood pH declines from baseline 7.4 7.4 7.4 down to ≈ 6.5 – 6.8 \approx 6.5\text{--}6.8 ≈ 6.5 – 6.8 .
Plasma Free Hemoglobin Increases ( ↑ \uparrow ↑ ) Spontaneous membrane vesiculation and micro-hemolysis occur (must remain < 1 % <1\% < 1% of total red cell mass).
Viable Cell Recovery Decreases ( ↓ \downarrow ↓ ) Regulatory standard requires ≥ 75 % \ge 75\% ≥ 75% 24-hour post-transfusion red cell survival in the recipient's circulation.
5. Donor Eligibility, Vital Signs, and Deferral Matrix
Parameter Acceptable Value / Standard Deferral Classification if Unmet
Age ≥ 18 years \ge 18\text{ years} ≥ 18 years (16–17 with written parental consent) Temporary until age criteria satisfied.
Weight ≥ 110 lbs \ge 110\text{ lbs} ≥ 110 lbs ( 50 kg 50\text{ kg} 50 kg ) for standard 450 mL 450\text{ mL} 450 mL bag Proportional volume reduction required if < 110 lbs <110\text{ lbs} < 110 lbs .
Hemoglobin Female: ≥ 12.5 g/dL \ge 12.5\text{ g/dL} ≥ 12.5 g/dL ; Male: ≥ 13.0 g/dL \ge 13.0\text{ g/dL} ≥ 13.0 g/dL ; Autologous: ≥ 11.0 g/dL \ge 11.0\text{ g/dL} ≥ 11.0 g/dL Temporary until hemoglobin normalizes.
Hematocrit Female: ≥ 38 % \ge 38\% ≥ 38% ; Male: ≥ 39 % \ge 39\% ≥ 39% ; Autologous: ≥ 33 % \ge 33\% ≥ 33% Temporary until hematocrit normalizes.
Blood Pressure Systolic 90–180 mm Hg; Diastolic 50–100 mm Hg Temporary (recheck on same day or defer until controlled).
Pulse Rate 50–100 bpm, regular (athletic bradycardia < 50 <50 < 50 acceptable) Temporary if irregular or pathologic; medical clearance.
Oral Temp ≤ 37.5 ∘ C \le 37.5^\circ\text{C} ≤ 37. 5 ∘ C ( 99.5 ∘ F 99.5^\circ\text{F} 99. 5 ∘ F ) Temporary until febrile episode completely resolves.
Venipuncture Site Bilateral antecubital area clear; no tracks or infection Permanent if needle tracks (illicit IV drugs); Temporary if skin rash.
HBsAg / Anti-HCV Non-reactive on screening and confirmatory assays Permanent / Indefinite deferral .
HIV / HTLV Non-reactive on screening and confirmatory assays Permanent / Indefinite deferral .
Viral Hepatitis No history at or after age 11 Permanent / Indefinite deferral (if ≥ 11 years old \ge 11\text{ years old} ≥ 11 years old ).
CJD / Dura Mater No personal or familial history; no cadaveric tissue Permanent / Indefinite deferral .
Measles, Mumps / Yellow Fever Received live attenuated vaccine Temporary: 2 weeks .
Rubella (incl. MMR) / Varicella Received live attenuated vaccine Temporary: 4 weeks (28 days) .
Tattoo / Piercing Recent procedure Temporary: 3 months (AABB); 12 months in services that keep the older rule .
Endemic Malaria Traveled to endemic area (1 yr); Lived in endemic area (3 yr) Temporary: 1 to 3 years .